Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Investing Activities (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Cash from Investing Activities data on record, last reported at $1.0 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 56.94% year-over-year to $1.0 million; the TTM value through Dec 2025 reached -$24.0 million, up 73.42%, while the annual FY2025 figure was -$24.0 million, 73.42% up from the prior year.
  • Cash from Investing Activities reached $1.0 million in Q4 2025 per MIRM's latest filing, up from -$2.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $108.0 million in Q4 2021 and bottomed at -$182.8 million in Q3 2023.
  • Average Cash from Investing Activities over 5 years is -$8.3 million, with a median of -$2.1 million recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: soared 2284.05% in 2021, then crashed 124007.69% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at $108.0 million in 2021, then tumbled by 75.23% to $26.8 million in 2022, then crashed by 107.47% to -$2.0 million in 2023, then skyrocketed by 132.05% to $641000.0 in 2024, then surged by 56.94% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $1.0 million in Q4 2025, -$2.2 million in Q3 2025, and -$6.6 million in Q2 2025.